迪哲医药(688192.SH)：上半年净亏损3.77亿元

Core Viewpoint - Dige Pharmaceutical (688192.SH) reported a significant increase in revenue for the first half of 2025, achieving 355 million yuan, a year-on-year growth of 74.40%, despite a net loss attributable to shareholders of 377 million yuan [1] Financial Performance - The company achieved a total revenue of 355 million yuan in the first half of 2025, marking a 74.40% increase compared to the previous year [1] - The net profit attributable to shareholders was a loss of 377 million yuan, with a basic earnings per share of -0.87 yuan [1] Research and Development - Continuous investment in research and development is identified as a key support for the company's high-quality growth, with ongoing efforts in the development of innovative drugs being a major factor influencing financial performance [1] - All products have been included in the medical insurance system, leading to a substantial increase in product sales revenue [1] - The company maintains a high level of overall R&D investment, with ongoing progress in products under development [1]